Novel Rx

EULAR19.abstract.jpg (keep)

EULAR 2023 – Day 4 Report

Jack Cush, MD
Jun 05, 2023

Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.  Many people missed the last day (June 3rd) of the meeting as a pending Milan airport strike on

Read Article
Magnifying glass

Clinically suspect arthralgias: justified or artefact?

David Liew
Jun 05, 2023

Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias. At EULAR 2023 in Milan, the perfect platform was provided for an airing of grievances, in a

Read Article
Targeted therapies in Sjogren’s syndrome: are we close? There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies. https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2

Links:

Dr. John Cush @RheumNow( View Tweet )
Jun 04, 2023
Puzzle pieces

Are T cells the missing link in pre-clinical RA?

Aurelie Najm, MD, PhD
Jun 03, 2023

T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA. 

Read Article
Target,T2T,bullseye

Targeted therapies in Sjogren’s syndrome: are we close?

Md Yuzaiful Md Yusof, MRCP(UK), PhD
Jun 03, 2023

There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.

 

Read Article
Wasn’t following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T, including meeting highlights by Christian Dejaco. Both look pretty exciting - the longer the sustained remission with CAR-T, the more it looks like maybe the real deal @RheumNow https://t.co/oKzb8ojTcz
David Liew @drdavidliew( View Tweet )
Jun 03, 2023
New 2023 @eular_org SLE recommendations Key changes, in response to evidence: - more caution re: steroids - biologics earlier - combo therapy (BEL or CNI/VCS) considered for lupus nephritis #EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
David Liew @drdavidliew( View Tweet )
Jun 03, 2023
#SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends @RheumNow #EULAR2023 https://t.co/Ylnnl3pHOK
Janet Pope @Janetbirdope( View Tweet )
Jun 03, 2023
Abstracts talking about #RA and JAKs and Biologic comparisons Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below @RheumNow https://t.co/jl5S4fLq19
Bella Mehta @bella_mehta( View Tweet )
Jun 03, 2023
Abatacept in pts at risk of #RA data from clinical trial. 213 pts, 31 centers. Pts with multiple autoantibodies improved the most with abatacept. @rheumnow #EULAR2023 https://t.co/c82jx0cAEq
Bella Mehta @bella_mehta( View Tweet )
Jun 03, 2023
Denosumab in hand OA prevented erosions! #eular2023 @RheumNow https://t.co/Ij2CVjh1ET
Bella Mehta @bella_mehta( View Tweet )
Jun 03, 2023
Treat early it is also cheaper! 5 yr cost of RA ttmt €11250 ACPA+ > €3526 ACPA- bDMARDS users €44788 ACPA+ > €40896 ACPA- ACPA- "late" ttmt 46% more expensive ACPA+ early vs. late = similar costs @Rheumnow #EULAR23 POS0369 https://t.co/dg9T9fqJDl
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 03, 2023
#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs. OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 03, 2023
Biosimilars cost less, but do they incur in indirect costs due to less dis control or more AE? DANBIO study (>1,300 pts w/ IA) Costs similar or decreased 9 mo after mandatory switching to ADA biosimilar (GP2017 or SB5) Decrease 15% GP2017 switchers #EULAR23 POS0376 @RheumNow https://t.co/bAeqYhNgf0
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 03, 2023
meds for PsA at #EULAR2023 recommendations bDMARD after csDMARD (no order proposed) @RheumNow https://t.co/bHMG4A8nmP
Bella Mehta @bella_mehta( View Tweet )
Jun 03, 2023
The thing that can influence bDMARD choice in PsA are the extra-MSK manifestations “A little bit of a paradigm shift here” - Laure Gossec 2023 @eular_org recommendations #EULAR2023 @RheumNow https://t.co/gr9IOg1bbj
David Liew @drdavidliew( View Tweet )
Jun 03, 2023
Which bDMARD first in PsA? 2023 @eular_org recommendation: no preferred order. All are equal in its eyes #EULAR2023 @RheumNow https://t.co/6HNNamAj1J
David Liew @drdavidliew( View Tweet )
Jun 03, 2023
How do we improve MTX adherence? Biochemical measure of MTX adherence 37% of patients starting a biologic do not take their MTX (!) Those who do respond better to first Biologic at 6 Mo than those who don’t 37% biologic responders = non adherent POS0313 #EULAR23 @Rheumnow https://t.co/L1Mkqpg1Aj
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 03, 2023
A mono therapy study RCT of TLL-018 vs #Tofa in RA subanalyses of previous JAKi exposure have not been done. Pts could have failed #Tofacitinib & enrolled so data could be divided to determine how this group responded. Safety looked good in both Rx LB0001 @RheumNow #EULAR2023 https://t.co/4kBHxWmk0q

Links:

Janet Pope @Janetbirdope( View Tweet )

Jun 03, 2023
exhibitor.floor.ACR

EULAR 2023 – Day 3 Report

Jack Cush, MD
Jun 02, 2023

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

Read Article
38420215_s.jpg

RA and cancer risk in the biologic era

Aurelie Najm, MD, PhD
Jun 02, 2023

A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer

Read Article
The key data for treating clinically suspect arthralgias (CSA): TREAT-EARLIER (MTX) ARIAA, APIPPRA (abatacept) but what we need to do going forward: stratify pts better for studies predict individual risk better, to weight up risk-benefit of intervention #EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
David Liew @drdavidliew( View Tweet )
Jun 02, 2023
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush @RheumNow( View Tweet )
Jun 02, 2023
#EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few years @RheumNow https://t.co/Oh8sZlMzUt
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 02, 2023
#EULAR2023 #POS0222 Post-hoc Analyses of Phase 3 RCT in Rituximab-treated ANCA vasculitis patients only (65% of total) showed more patients met Remission rate & with lower GC Toxicity vs Pred Taper + RTX at 52 weeks, consistent with Trial Main Results @RheumNow https://t.co/BmiujbhQI9
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 02, 2023

Recent Blogs

ICYMI: The Biosimilar "Buy In"

Rachel Tate, DO
May 29, 2023
Biosimiars
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients.  Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023. Read Post

    Do you get our email newsletter?

    Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

    Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

    Copyright 2023 All Rights Reserved.

    ×